包括優必選(09880.HK)等25間重點企業簽約落戶香港
政府引進重點企業辦公室舉行「重點企業夥伴簽約儀式」,涉及25間企業,當中6間是在去年10月引進,而19間是新一批的重點企業。在新一批重點企業中,有14間來自內地,包括優必選(09880.HK)及生物醫藥公司優銳醫藥等,而其餘5間來自美國,包括美國物流支付平台PayCargo,以及賽諾菲(Sanofi)與百度(09888.HK)創辦人李彥宏所創立的AI創新藥物開發公司百圖生科(BioMap)等。
行政長官李家超表示,今次簽約的企業連同去年10月公布的首批約30間重點企業,合共已有約50間重點企業,預計未來數年會在香港投資超過400億元,創造超過1.3萬個就業機會。財政司長陳茂波亦稱,引進辦在今年內會至少接觸300間重點企業,未來亦會與更多重點企業簽約。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.